Treatment of small cell lung cancer: Challenges and prospects / 医学研究生学报

ABSTRACT

Currently, chemotherapy remains the first- and second-line standard treatment of small cell lung cancer (SCLC). line treatment strategies. In terms of targeted therapies, the antibody-conjugated drug lubbinectedin was granted Orphan Drug Designation by US FDA for its objective response rate of 39.3%. Goals have been achieved in the primary endpoint of progression-free survival, secondary endpoint overall survival and disease control rate of the third-line or further treatment of SCLC in phase-II ALTER 1202 trial of anlotinib, with satisfactory therapeutic results. Anlotinib maintenance therapy after first-line chemotherapy, anlotinib combined with immunotherapy, and identification of the population truly suitable for anlotinib treatment will be most important directions for the future studies.